Production of tag-free recombinant fusion protein encompassing promiscuous T cell epitope of tetanus toxoid and dog zona pellucida glycoprotein-3 for contraceptive vaccine development

Molecular Biotechnology

Volumn 54, Issue 3, 2013, Pages 853-862

  Gupta, Neha ^a   Shrestha, Abhinav ^a   Panda, Amulya Kumar ^a   Gupta, Satish Kumar ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Contraceptive vaccine; Dog zona pellucida glycoprotein 3; Inclusion bodies; Protein folding; Tag free recombinant protein purification

Indexed keywords

FLUORESCENT SPECTROSCOPY; GUANIDINE HYDROCHLORIDE; HOST CELL PROTEIN; INCLUSION BODIES; PHYSICOCHEMICAL PROPERTY; RECOMBINANT PROTEIN PURIFICATION; VACCINE DEVELOPMENT; ZONA PELLUCIDA;

AMINO ACIDS; ANTIBODIES; EPITOPES; ESCHERICHIA COLI; GLYCOPROTEINS; IMMUNIZATION; MAMMALS; PROTEIN FOLDING; PURIFICATION; VACCINES;

RECOMBINANT PROTEINS;

CONTRACEPTIVE VACCINE; DOG ZONA PELLUCIDA GLYCOPROTEIN 3; EPITOPE; GLYCOPROTEIN; GUANIDINE; HYBRID PROTEIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CELL INCLUSION; CIRCULAR DICHROISM; DOG; ESCHERICHIA COLI; FLUORESCENCE SPECTROSCOPY; IMMUNIZATION; IMMUNOGENICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SOLUBILIZATION; ZONA PELLUCIDA;

ANIMALS; CIRCULAR DICHROISM; CLONING, MOLECULAR; DOGS; EGG PROTEINS; EPITOPES, T-LYMPHOCYTE; FEMALE; INCLUSION BODIES; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SPECTROMETRY, FLUORESCENCE; TETANUS TOXOID; VACCINES, CONTRACEPTIVE;

CANIS FAMILIARIS; ESCHERICHIA COLI; MUS;

EID: 84882873835     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-012-9634-4     Document Type: Article

References (39)

1. Afzalpurkar, A.; Gupta, S. K. (1997). Identification of epitopes of monoclonal antibodies to porcine zona pellucida 3 beta glycoprotein, a homologue of the mouse/human sperm receptor. American Journal of Reproductive Immunology, 38, 26-32.
2. Bondos, S. E.; Bicknell, A. (2003). Detection and prevention of protein aggregation before, during, and after purification. Analytical Biochemistry, 316, 223-231.
3. Clark, E. D. (2001). Protein refolding for industrial processes. Current Opinion in Biotechnology, 12, 202-207.
4. Cui, X.; Duckworth, J. A.; Molinia, F. C.; Cowan, P. E. (2010). Identification and evaluation of an infertility-associated ZP3 epitope from the marsupial brushtail possum (Trichosurus vulpecula). Vaccine, 28, 1499-1505.
5. Gatti-Lafranconi, P.; Natalello, A.; Ami, D.; Doglia, S. M.; Lotti, M. (2011). Concepts and tools to exploit the potential of bacterial inclusion bodies in protein science and biotechnology. FEBS Journal, 278, 2408-2418.
6. Greenfield, N. J. (2006). Using circular dichroism spectra to estimate protein secondary structure. Nature Protocols, 1, 2876-2890.
7. Gupta, S. K.; Bansal, P. (2010). Vaccines for immunological control of fertility. Reproductive Medicine and Biology, 9, 61-71.
8. Gupta, S. K.; Gupta, N.; Suman, P.; Choudhury, S.; Prakash, K.; Gupta, T.; et al. (2011). Zona pellucida-based contraceptive vaccines for human and animal utility. Journal of Reproductive Immunology, 88, 240-246.
9. Harris, J. D.; Seid, C. A.; Fontenot, G. K.; Liu, H. F. (1999). Expression and purification of recombinant human zona pellucida proteins. Protein Expression and Purification, 16, 298-307.
10. Ho, P. C.; Mutch, D. A.; Winkel, K. D.; Saul, A. J.; Jones, G. L.; Doran, T. J.; et al. (1990). Identification of two 'promiscuous' T cell epitopes from tetanus toxin. European Journal of Immunology, 20, 477-483.
11. Jovel, S. R.; Kumagai, T.; Danshiitsoodol, N.; Matoba, Y.; Nishimura, M.; Sugiyama, M. (2006). Purification and characterization of the second Streptomyces phospholipase A2 refolded from an inclusion body. Protein Expression and Purification, 50, 82-88.
12. Kaul, R.; Afzalpurkar, A.; Gupta, S. K. (1997). Expression of bonnet monkey (Macaca radiata) zona pellucida-3 (ZP3) in a prokaryotic system and its immunogenicity. Molecular Reproduction and Development, 47, 140-147.
13. Kelly, S. M.; Jess, T. J.; Price, N. C. (2005). How to study proteins by circular dichroism? Biochimica et Biophysica Acta, 1751, 119-139.
14. Khan, F.; Legler, P. M.; Mease, R. M.; Duncan, E. H.; Bergmann-Leitner, E. S.; Angov, E. (2012). Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Biotechnology Journal, 7, 133-147.
15. Kirkpatrick, J. F.; Liu, I. K. M.; Turner, J. W, Jr. (1990). Remotely-delivered immunocontraception in feral horses. Wildlife Society Bulletin, 18, 326-330.
16. Kitchener, A. L.; Harman, A.; Kay, D. J.; McCartney, C. A.; Mate, K. E.; Rodger, J. C. (2009). Immunocontraception of eastern grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein. Journal of Reproductive Immunology, 79, 156-162.
17. Klose, J.; Wendt, N.; Kubald, S.; Krause, E.; Fechner, K.; Beyermann, M.; et al. (2004). Hexa-histidine tag position influences disulfide structure but not binding behavior of in vitro folded N-terminal domain of rat corticotropin-releasing factor receptor type 2a. Protein Science, 13, 2470-2475.
18. Korepanova, A.; Douglas, C.; Leyngold, I.; Logan, T. M. (2001). N-terminal extension changes the folding mechanism of the FK506-binding protein. Protein Science, 10, 1905-1910.
19. Kuo, W. H.; Chase, H. A. (2010). Process intensification for the removal of poly-histidine fusion tags from recombinant proteins by an exopeptidase. Biotechnology Progress, 26, 142-149.
20. Lairmore, M. D.; DiGeorge, A. M.; Conrad, S. F.; Trevino, A. V.; Lal, R. B.; Kaumaya, P. T. (1995). Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T cell epitopes enhance immunogenicity and overcome genetic restriction. Journal of Virology, 69, 6077-6089.
21. Lennon-Dumenil, A. M.; Bakker, A. H.; Wolf-Bryant, P.; Ploegh, H. L.; Lagaudri'ere-Gesbert, C. (2002). A closer look at proteolysis and MHC class-II restricted antigen presentation. Current Opinion in Immunology, 14, 15-21.
22. Mahi-Brown, C. A.; Yanagimachi, R.; Hoffman, J. C.; Huang, T. T, Jr. (1985). Fertility control in the bitch by active immunization with porcine zonae pellucidae: use of different adjuvants and patterns of estradiol and progesterone levels in estrous cycles. Biology of Reproduction, 32, 761-772.
23. Mahi-Brown, C. A.; Yanagimachi, R.; Nelson, M. L.; Yanagimachi, H.; Palumbo, N. (1988). Ovarian histopathology of bitches immunized with porcine zonae pellucidae. American Journal of Reproductive Immunology Microbiology, 18, 94-103.
24. McShea, W. J.; Monfort, S. L.; Hakim, S.; Kirkpatrick, J. F.; Liu, I. K. M.; Turner, J. W, Jr, et al. (1997). Immunocontraceptive efficacy and the impact of contraception on the reproductive behaviors of white-tailed deer. Journal of Wildlife Management, 61, 560-569.
25. Meslin, F. X.; Fishbein, D. B.; Matter, H. C. (1994). Rationale and prospects for rabies elimination in developing countries. Current Topics in Microbiology and Immunology, 187, 1-26.
26. Morell, M.; Bravo, R.; Espargaro, A.; Sisquella, X.; Aviles, F. X.; Fernàndez-Busquets, X.; et al. (2008). Inclusion bodies: specificity in their aggregation process and amyloid-like structure. Biochimica et Biophysica Acta, 1783, 1815-1825.
27. Oishi, Y.; Onozuka, A.; Kato, H.; Shimura, N.; Imai, S.; Nisizawa, T. (2001). The effect of amino acid spacers on the antigenicity of dimeric peptide inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiology and Immunology, 16, 40-44.
28. Panda, A. K. (2003). Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli. Advances in Biochemical Engineering/Biotechnology, 85, 43-93.
29. Parker, R.; Deville, S.; Dupuis, L.; Bertrand, F.; Aucouturier, J. (2009). Adjuvant formulation for veterinary vaccines: Montanide™ Gel safety profile. Procedia in Vaccinology, 1, 140-147.
30. Paterson, M.; Wilson, M. R.; Morris, K. D.; van Duin, M.; Aitken, R. J. (1998). Evaluation of the contraceptive potential of recombinant human ZP3 and human ZP3 peptides in a primate model: their safety and efficacy. American Journal of Reproductive Immunology, 40, 198-209.
31. Rath, A.; Glibowicka, M.; Nadeau, V. G.; Chen, G.; Deber, C. M. (2009). Detergent binding explains anomalous SDS-PAGE migration of membrane proteins. Proceedings of the National Academy of Sciences of the United States of America, 106, 1760-1765.
32. Sacco, A. G.; Yurewicz, E. C.; Subramanian, M. G.; DeMayo, F. J. (1981). Zona pellucida composition: species cross reactivity and contraceptive potential of the antiserum to a purified pig zona antigen (PPZA). Biology of Reproduction, 25, 997-1008.
33. Santhanam, R.; Panda, A. K.; Kumar, V. S.; Gupta, S. K. (1998). Dog zona pellucida glycoprotein-3 (ZP3): expression in Escherichia coli and immunological characterization. Protein Expression and Purification, 12, 331-339.
34. Speed, M. A.; Wang, D. I. C.; King, J. (1996). Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nature Biotechnology, 14, 1283-1287.
35. Srivastava, N.; Santhanam, R.; Sheela, P.; Mukund, S.; Thakral, S. S.; Malik, B. S.; et al. (2002). Evaluation of the immunocontraceptive potential of Escherichia coli-expressed recombinant dog ZP2 and ZP3 in a homologous animal model. Reproduction, 123, 847-857.
36. Svensson, J.; Andersson, C.; Reseland, J. E.; Lyngstadaas, P.; Bulow, L. (2006). Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli. Protein Expression and Purification, 48, 134-141.
37. Ventura, S.; Villaverde, A. (2006). Protein quality in bacterial inclusion bodies. Trends in Biotechnology, 24, 179-185.
38. Villaverde, A.; Carrió, M. M. (2003). Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnology Letters, 25, 85-95.
39. Woestenenk, E. A.; Hammarstrom, M.; van den Berg, S.; Hard, T.; Berglund, H. (2004). His tag effect on solubility of human proteins produced in Escherichia coli: A comparison between four expression vectors. Journal of Structural and Functional Genomics, 5, 217-229.